Fig. 1From: Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trialFlowchart of treatments for the trial. *Risk group defined as per National Comprehensive Center Network (NCCN) guidelinesBack to article page